If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-28. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
For services to the Arts and to the community in Southend-on-Sea, Essex. Dr. Alasdair Cunningham Bruce. Boston Spa Renewed Programme Manager. For services to Libraries. Christopher John Paul Bryant. Director of Tournaments and Events, Football Association. For services to Sport. Jennifer Sheridan Bryer. Teacher, Pony Club. For services to Horse Riding. Peter George Buchan. Managing Director, Shipping, Nuclear Transport Solutions. For services to the Nuclear Industry and to Young People. Khumi Tonsing Burton, JP, DL. For services to the community in Manchester and Cheshire. Ronald Butler. Policy Adviser, Department for Work and Pensions. For services to Disadvantaged People. Carrie Byrom. Director, Stable Lives. For services to Mental Health and the community in North West England. David Corrie Calvert. President, Langholm Town Band. For services to the community in Langholm, Dumfries. Carl Campbell. Founder and Artistic Director, CCDC7. For services to African Caribbean Dance Education and Culture. Catriona Yvonne Fiona Campbell. UK&I Chief Technology and Innovation Officer, EY. For services to Technology and Innovation. George Alan Carney. Executive Officer, Department for Education. For Public Service. Professor Kathryn Janice Carruthers. Professor of French Linguistics, Queen's University Belfast. For services to Modern Languages. Kathryn Melanie Keele Caton. Founder and Managing Director, Brighton Gin. For services to Trade and to the community in Brighton. Amanda Chadwick. Founder and Trustee, Pyjama Fairies. For services to Children in Hospital. Edward Kay Kiu Chan.
=== Structural Biology and Protein Engineering === This program studies biomolecules using protein engineering and molecular biology techniques. Methodologies include X-ray crystallography and cryo-EM. Research includes protein structure determination and mass spectrometry methods.
McCoy warned that, if China's numerous breaches on Taiwan become "a crippling embargo of Taiwan", the US would lose Taiwan, risking a break of "America's island chain in the Pacific littoral, pushing it back to a 'second island chain' in the mid-Pacific", regardless of the US's decisions on Taiwan. He further cited growing anti-American sentiment in the Philippines, the opposition toward AUKUS (trilateral security partnership between Australia, the United Kingdom, and the United States) from certain members of the Labor Party as a threat to Australia's sovereignty, and the Republican Party populism in the US under Trump (or his successor-in-line JD Vance) potentially curtailing the US's ability to maintain its alliance with the Asia-Pacific countries. In January 2025, almost two weeks before Biden ended his term, Hoover Institution senior fellow Niall Ferguson wrote that the US has had "a second cold war" with China for at least six years and that the war further intensified under the Biden administration. Ferguson drew comparisons between Trump and then-US president Ronald Reagan, like assassination attempts on them, but further suggested that Trump use the Reagan administration's past approach in foreign policy.
Sources: en.wikipedia.org
== Biomedical applications == DNA origami, being made of a natural biological polymer, is well suited to the biological environment when salt concentrations allow, and offers fine control over the positioning of molecules and structures in the system. This allows DNA origami to be applicable to a number of scenarios in biomedical engineering. Current biomedical applications include drug release with 0 order mechanisms, vaccines, cell signaling, and sensing applications. DNA is folded into an octahedron and coated with a single bilayer of phospholipid, mimicking the envelope of a virus particle. The DNA nanoparticles, each at about the size of a virion, are able to remain in circulation for hours after being injected into mice. It also elicits a much lower immune response than the uncoated particles. It presents a potential use in drug delivery, reported by researchers at the Wyss Institute at Harvard University. Researchers at the Harvard University Wyss Institute reported the self-assembling and self-destructing drug delivery vessels using the DNA origami in the lab tests. The DNA nanorobot they created is an open DNA tube with a hinge on one side which can be clasped shut. The drug filled DNA tube is held shut by a DNA aptamer, configured to identify and seek certain diseased related protein. Once the origami nanobots get to the infected cells, the aptamers break apart and release the drug. The first disease model the researchers used was leukemia and lymphoma.
The Times reported that while one child in 20 in Shanghai could have kidney damage as a result of drinking contaminated formula milk, on the other hand, "like the emperors of old, the new communist elite enjoy the finest produce from all over China, sourced by a high-security government department." Access Asia, a Shanghai-based consumer consultancy, said Fonterra was an example of western executives in China "believ[ing] advice in business books that they must avoid making their local partners 'lose face' at all costs". It suggested that Fonterra paid the price for this both financially and in damage to their reputation. Caijing said the crisis revealed that there had been a "serious dereliction of duty" at the AQSIQ, and that the government had failed as a "night watchman". Citing public consensus that government should limit itself to a supervisory role, it urged the construction of a regulatory system which addressed the role of regulators watching over the production process, avoiding over-regulation, 'regulatory capture' and abuse of power by regulators. "Keeping the market in order and ensuring independent law enforcement should be part of the mandate."
Dihydropyridines (DHP): amlodipine, nifedipine, felodipine, nicardipine Non-dihydropyridines (non-DHP): diltiazem, verapamil In general, the side effects of CCBs include peripheral edema and gingival hyperplasia when CCBs are used chronically. To add on, DHP may cause reflex tachycardia and peripheral edema, while non-DHP may cause bradycardia and worsening of cardiac function due to reduced cardiac contractility and cardiac conduction. Non-dihydropyridines are contraindicated in patients with heart failure with reduced ejection fraction (HFrEF), and second- or third-degree atrioventricular block. Special attention should be given to the coadministration of non-DHP with beta-blockers or ivabradine due to the increased risk of bradycardia. Since both DHP and non-DHP are metabolized through the CYP3A4 system, grapefruit juice containing furanocoumarins (the potent inhibitors of the CYP3A4 enzyme) should be avoided.
==== Declined ==== Beto Altamirano, tech entrepreneur and candidate for mayor of San Antonio in 2025 Greg Casar, incumbent U.S. representative from the 35th district Philip Cortez, state representative from the 117th district (2013–2015, 2017–present) (running for re-election) Roland Gutierrez, state senator from the 19th district (2021–present) and candidate for U.S. senate in 2024 (running for re-election)
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.